pharmaceuticals-and-healthcare

Global RNAi for Therapeutic Consumption Market 2016 Industry Trend and Forecast 2021


Published On : Jul 2016

Category : Biotechnology

No. of Pages : 129 pages

  • $4000
  • $8000

Please click below to avail discount on this report

The Global RNAi for Therapeutic Consumption Market 2016 Industry Trend and Forecast 2021 is a professional and in-depth study on the current state of the RNAi for Therapeutic market.

The report provides a basic overview of the RNAi for Therapeutic industry including definitions, classifications, applications and industry chain structure.

Development policies and plans are discussed as well as manufacturing processes are also analyzed. 

The report then analyzes the global RNAi for Therapeutic expenses, and the sales segment market is also discussed by product type, applications and region.

The major RNAi for Therapeutic market (including United States, Europe, etc.) is analyzed, data including: market size, expenses segment market by product type and applications. Then we forecast the 2016-2025 market size of RNAi for Therapeutic.

The report focuses on global major leading companies providing information such as company profiles, expenses, R&D expenses and contact information.
 
Finally the marketing, feasibility of new investment projects are assessed and overall research conclusions offered.

With 163 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

A massive portion of the overall impetus that players and markets associated with biotechnology are receiving, comes from the rapidly increasing government support. Developed economies are especially ahead of the game in terms of research and development, as well as the incorporation of ready products into the commercial markets. However, it should be noted that the average time to market for a standard biotechnology product is exceedingly higher than conventional medical products. Despite this, players are becoming ever ready to tackle the more promising fields in biotechnology, namely stem cell technology, nanotechnology, and genetic cloning. This field is poised to be an inseparable part of the healthcare industry, and is in need of heavy efforts on the research and development side.

The Global rnai for therapeutic consumption market 2016 industry trend and forecast 2021 is a very different market loaded with exceptional competitors and very specific customer and end user appeals. The improvement of innovations is additionally in high demand, with the developed economies demonstrating a more prominent consideration in the advancement of cutting edge advances than the developing economies. The report considers every such element while surveying the upcoming expected openings for players in the market over the coming years. It therefore converts the data presented into a matter of point of view, and offers the most ideal one for the market as far as getting favored by the key drivers and patterns influencing the market is concerned, while evading the hindrances that could prevent the advance of the players. The establishment for this investigation is made by getting the readers of this report familiar with the basic syntax of the market as it is important to completely comprehend its progression that the said entities are expected to promote themselves on.

The regional examination of the Global rnai for therapeutic consumption market 2016 industry trend and forecast 2021 can be depicted as a widely inclusive survey of the key locations, from the points of view of these locations as specified through their existing player base and the general end user reports for them. This is a doubly useful approach in market examination for the regional companies, as it helps them see precisely what their field of operation needs, as far as their end users are concerned. Moreover, investors will be able to figure out which organization they can pay special attention to when attempting to extend their investments profiles. Additionally, the level of detail with which every segment and region is depicted can build this report up to be a convenient guide for them with regards to enhancing their place in a particular region or country, or with regards to entering new market fruitfully over the coming years.

The competitive analysis presented in the report on the Global rnai for therapeutic consumption market 2016 industry trend and forecast 2021 can be an imperative device in the overall arsenal that a market player possesses. A careful learning and understanding of the competitive profiles and the contentions between players is a crucial bit of data needed by all market players, and it is the thing that this report gives to every client. The level of customization for every player takes into consideration an extraordinary standpoint for them, taking into account significantly more noteworthy data.

Table of Contents

1 Industry Overview 1
1.1 Definition and Specifications of RNAi for Therapeutic 1
1.1.1 Definition of RNAi for Therapeutic 1
1.1.2 Mechanism and Development History RNAi for Therapeutic 2
1.2 Classification of RNAi for Therapeutic 2
1.2.1 siRNA 3
1.2.2 miRNA 4
1.2.3 shRNA 5
1.3 Applications of RNAi for Therapeutic 7
1.3.1 Cancer 8
1.3.2 Cardiovascular 8
1.3.3 HBV 9
1.4 Industry Chain Structure of RNAi for Therapeutic 10
1.5 Industry Overview and Major Regions Status of RNAi for Therapeutic 10
1.5.1 Industry Overview of RNAi for Therapeutic 10
1.5.2 Global Major Regions Status of RNAi for Therapeutic 12
1.6 Industry Policy Analysis of RNAi for Therapeutic 12
1.7 Industry News Analysis of RNAi for Therapeutic 14
2 Technical Data and Manufacturing Plants Analysis 16
2.1 Expenses and Commercial Expenses Date of Global Key Manufacturers in 2015 16
2.2 Headquarter of Global Key RNAi for Therapeutic Manufacturers in 2015 16
2.3 R&D Status and Technology Type of Global RNAi for Therapeutic Key Manufacturers 17
2.4 Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 18
2.5 Pipeline Analysis of Global RNAi for Therapeutic Key Manufacturers in 2015 19
2.5.1 Alnylam Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic 19
2.5.2 Arbutus Biopharma (Tekmira) Pipeline Analysis of RNAi for Therapeutic 20
2.5.3 Arrowhead Research Pipeline Analysis of RNAi for Therapeutic 21
2.5.4 Dicerna Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic 22
2.5.5 Mirna Therapeutics Pipeline Analysis of RNAi for Therapeutic 23
2.5.6 Quark Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic 24
2.5.7 RXi Pharmaceuticals Pipeline Analysis of RNAi for Therapeutic 25
2.5.8 Silence Therapeutics Pipeline Analysis of RNAi for Therapeutic 26
2.5.9 Benitec Biopharma Pipeline Analysis of RNAi for Therapeutic 27
2.5.10 miRagen Therapeutics Pipeline Analysis of RNAi for Therapeutic 28
2.5.11 Sylentis Pipeline Analysis of RNAi for Therapeutic 29
2.5.12 Gradalis Pipeline Analysis of RNAi for Therapeutic 29
2.5.13 Sirnaomics Pipeline Analysis of RNAi for Therapeutic 30
2.5.14 Silenseed Pipeline Analysis of RNAi for Therapeutic 31
3 Global RNAi for Therapeutic Expenses 2011-2016 Analysis 32
3.1 Global 2011-2016E RNAi for Therapeutic Expenses Analysis 32
3.2 Global 2011-2016E RNAi for Therapeutic Expenses by Companies 32
3.3 Global 2011-2016E RNAi for Therapeutic Expenses by Product Type 34
3.4 Global 2011-2016E RNAi for Therapeutic Expenses by Applications 35
3.5 Global 2011-2016E RNAi for Therapeutic Expenses by Region 37
4 United States RNAi for Therapeutic Expenses Analysis 39
4.1 United States 2011-2016E RNAi for Therapeutic Expenses Analysis 39
4.2 United States 2011-2016E RNAi for Therapeutic Expenses by Companies 39
4.3 United States 2011-2016E RNAi for Therapeutic Expenses by Product Type 40
4.4 United States 2011-2016E RNAi for Therapeutic Expenses by Applications 42
5 Europe RNAi for Therapeutic Expenses Analysis 44
5.1 Europe 2011-2016E RNAi for Therapeutic Expenses Analysis 44
5.2 Europe 2011-2016E RNAi for Therapeutic Expenses by Companies 44
5.3 Europe 2011-2016E RNAi for Therapeutic Expenses by Product Type 45
5.4 Europe 2011-2016E RNAi for Therapeutic Expenses by Applications 47
6 Other Region RNAi for Therapeutic Expenses Analysis 49
6.1 Other Region 2011-2016E RNAi for Therapeutic Expenses Analysis 49
6.2 Other Region 2011-2016E RNAi for Therapeutic Expenses by Companies 49
6.3 Other Region 2011-2016E RNAi for Therapeutic Expenses by Product Type 50
6.4 Other Region 2011-2016E RNAi for Therapeutic Expenses by Applications 52
7 Market Size of RNAi for Therapeutic Forecast by Region, Type and Application 2016-2025 54
7.1 Market Size (M USD) of RNAi for Therapeutic Forecast by Region 54
7.2 Market Size (M USD) of RNAi for Therapeutic Forecast by Type 56
7.3 Market Size (M USD) of RNAi for Therapeutic Forecast by Application 57
8 Global and Major Regions 2016-2021 RNAi for Therapeutic Expenses Forecast 59
8.1 Global 2016-2021 RNAi for Therapeutic Expenses Forecast 59
8.2 United States 2016-2021 RNAi for Therapeutic Expenses Forecast 60
8.3 Europe 2016-2021 RNAi for Therapeutic Expenses Forecast 61
8.4 Other Region 2016-2021 RNAi for Therapeutic Expenses Forecast 62
9 Analysis of RNAi for Therapeutic Industry Key Manufacturers 63
9.1 Alnylam Pharmaceuticals 63
9.1.1 Company Profile 63
9.1.2 Research Information 64
9.1.3 Expenses, R&D Expenses and R&D Share 64
9.2 Arbutus Biopharma (Tekmira) 66
9.2.1 Company Profile 66
9.2.2 Research Information 66
9.2.3 Expenses, R&D Expenses and R&D Share 67
9.3 Arrowhead Research 69
9.3.1 Company Profile 69
9.3.2 Research Information 70
9.3.3 Expenses, R&D Expenses and R&D Share 70
9.4 Dicerna Pharmaceuticals 72
9.4.1 Company Profile 72
9.4.2 Research Information 73
9.4.3 Expenses, R&D Expenses and R&D Share 73
9.5 Mirna Therapeutics 75
9.5.1 Company Profile 75
9.5.2 Research Information 76
9.5.3 Expenses, R&D Expenses and R&D Share 76
9.6 Quark Pharmaceuticals 78
9.6.1 Company Profile 78
9.6.2 Research Information 79
9.6.3 Expenses, R&D Expenses and R&D Share 79
9.7 RXi Pharmaceuticals 81
9.7.1 Company Profile 81
9.7.2 Research Information 82
9.7.3 Expenses, R&D Expenses and R&D Share 83
9.8 Silence Therapeutics 84
9.8.1 Company Profile 84
9.8.2 Research Information 85
9.8.3 Expenses, R&D Expenses and R&D Share 86
9.9 Benitec Biopharma 87
9.9.1 Company Profile 87
9.9.2 Research Information 88
9.9.3 Expenses, R&D Expenses and R&D Share 88
9.10 miRagen Therapeutics 90
9.10.1 Company Profile 90
9.10.2 Research Information 91
9.10.3 Expenses, R&D Expenses and R&D Share 92
9.11 Sylentis 93
9.11.1 Company Profile 93
9.11.2 Research Information 94
9.11.3 Expenses, R&D Expenses and R&D Share 95
9.12 Gradalis 96
9.12.1 Company Profile 96
9.12.2 Research Information 97
9.12.3 Expenses, R&D Expenses and R&D Share 97
9.13 Sirnaomics 99
9.13.1 Company Profile 99
9.13.2 Research Information 100
9.13.3 Expenses, R&D Expenses and R&D Share 100
9.14 Silenseed 102
9.14.1 Company Profile 102
9.14.2 Research Information 103
9.14.3 Expenses, R&D Expenses and R&D Share 103
10 Global RNAi for Therapeutic Expenses Analysis 105
10.1 2011-2016E Global RNAi for Therapeutic Expenses by Countries 105
10.2 2011-2016E Global RNAi for Therapeutic Expenses Market Share 105
11 Manufacturing Process and Collaborations Analysis of RNAi for Therapeutic 108
11.1 Manufacturing Process Analysis of RNAi for Therapeutic 108
11.2 Key Manufacturer’s Collaborations of RNAi for Therapeutic 108
12 New Project SWOT Analysis of RNAi for Therapeutic 112
13 Conclusion of the Global RNAi for Therapeutic Consumption Market 2016 Industry Trend and Forecast 2021 113

Figure Picture of RNAi for Therapeutic 1
Table Classification of RNAi for Therapeutic 2
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Product Type 3
Figure siRNA Picture 4
Figure miRNA Picture 5
Figure shRNA Picture 6
Table the differences between siRNA and shRNA 6
Table Applications of RNAi for Therapeutic 7
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Applications 8
Figure Industry Chain Structure of RNAi for Therapeutic 10
Table Global RNAi for Therapeutic Major Manufacturers 11
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Region 12
Table Industry Policy of RNAi for Therapeutic 12
Table Industry News List of RNAi for Therapeutic 14
Table Expenses (K USD) and Commercial Expenses Date of Global RNAi for Therapeutic Key Manufacturers in 2015 16
Table Headquarter of Global RNAi for Therapeutic Major Manufacturers in 2015 16
Table R&D Status and Technology Type of Global RNAi for Therapeutic Key Manufacturers 17
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 18
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 19
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 20
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 21
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 22
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 23
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 24
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 25
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 26
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 27
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 28
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 29
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 29
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 30
Table Therapeutic Areas Analysis of Global RNAi Technology Key Manufacturers in 2015 31
Figure Global 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate 32
Table Global 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD) 32
Table Global 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies 33
Table Global 2011-2016E RNAi for Therapeutic Expenses (K USD) by Product Type 34
Figure Global 2011 RNAi for Therapeutic Expenses Market Share by Product Type 34
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Product Type 35
Table Global 2011-2016E RNAi for Therapeutic Expenses (K USD) by Applications 35
Figure Global 2011 RNAi for Therapeutic Expenses Market Share by Applications 36
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Applications 36
Table Global 2011-2016E RNAi for Therapeutic Expenses (K USD) by Region 37
Figure Global 2011 RNAi for Therapeutic Expenses Market Share by Region 37
Figure Global 2015 RNAi for Therapeutic Expenses Market Share by Region 38
Figure United States 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate 39
Table United States 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD) 39
Table United States 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies 40
Table United States 2011-2016E RNAi for Therapeutic Expenses by Product Type 40
Figure United States 2011 RNAi for Therapeutic Expenses Market Share by Product Type 41
Figure United States 2015 RNAi for Therapeutic Expenses Market Share by Product Type 41
Table United States 2011-2016E RNAi for Therapeutic Expenses (K USD) by Applications 42
Figure United States 2011 RNAi for Therapeutic Expenses Market Share by Applications 42
Figure United States 2015 RNAi for Therapeutic Expenses Market Share by Applications 43
Figure Europe 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate 44
Table Europe 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD) 44
Table Europe 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies 45
Table Europe 2011-2016E RNAi for Therapeutic Expenses by Product Type (K USD) 45
Figure Europe 2011 RNAi for Therapeutic Expenses Market Share by Product Type 46
Figure Europe 2015 RNAi for Therapeutic Expenses Market Share by Product Type 46
Table Europe 2011-2016E RNAi for Therapeutic Expenses by Applications (K USD) 47
Figure Europe 2011 RNAi for Therapeutic Expenses Market Share by Applications 47
Figure Europe 2015 RNAi for Therapeutic Expenses Market Share by Applications 48
Figure Other Region 2011-2016E RNAi for Therapeutic Expenses (K USD) and Growth Rate 49
Table Other Region 2011-2016E RNAi for Therapeutic Expenses and Total Expenses (K USD) 49
Table Other Region 2011-2016E RNAi for Therapeutic Expenses Market Share by Companies 50
Table Other Region 2011-2016E RNAi for Therapeutic Expenses (K USD) by Product Type 50
Figure Other Region 2011 RNAi for Therapeutic Expenses Market Share by Product Type 51
Figure Other Region 2015 RNAi for Therapeutic Expenses Market Share by Product Type 51
Table Other Region 2011-2016E RNAi for Therapeutic Expenses by Applications (K USD) 52
Figure Other Region 2011 RNAi for Therapeutic Expenses Market Share by Applications 52
Figure Other Region 2015 RNAi for Therapeutic Expenses Market Share by Applications 53
Table Market Size (M USD) of RNAi for Therapeutic Forecast by Region 54
Figure Global Market Size (M USD) and Growth Rate of RNAi for Therapeutic 54
Figure United States Market Size (M USD) and Growth Rate of RNAi for Therapeutic 55
Figure Europe Market Size (M USD) and Growth Rate of RNAi for Therapeutic 55
Figure Asia Market Size (M USD) and Growth Rate of RNAi for Therapeutic 56
Table Market Size (M USD) of RNAi for Therapeutic Forecast by Type 56
Figure RNAi for Therapeutic Forecast by Type Market Share by Type in 2025 57
Table Market Size (M USD) of RNAi for Therapeutic Forecast by Application 57
Figure RNAi for Therapeutic Forecast by Type Market Share by Application in 2025 58
Figure Global 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast 59
Figure United States 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast 60
Figure Europe 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast 61
Figure Other Region 2016-2021 RNAi for Therapeutic Expenses (K USD) and Growth Rate Forecast 62
Table Alnylam Pharmaceuticals Company Profile 63
Figure Research Picture of Alnylam Pharmaceuticals 64
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Alnylam Pharmaceuticals 2011-2016 64
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Alnylam Pharmaceuticals 2011-2016 65
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Alnylam Pharmaceuticals 2011-2016 65
Table Arbutus Biopharma (Tekmira) Company Profile 66
Figure RNAi for Therapeutic Research Information of Arbutus Biopharma (Tekmira) 66
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Arbutus Biopharma (Tekmira) 2011-2016 67
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Arbutus Biopharma (Tekmira) 2011-2016 68
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Arbutus Biopharma (Tekmira) 2011-2016 68
Table Arrowhead Research Company Profile 69
Figure Helixate FS Research Information of Arrowhead Research 70
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Arrowhead Research 2011-2016 70
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Arrowhead Research 2011-2016 71
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Arrowhead Research 2011-2016 71
Table Dicerna Pharmaceuticals Company Profile 72
Figure Research Information of Dicerna Pharmaceuticals 73
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Dicerna Pharmaceuticals 2011-2016 73
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Dicerna Pharmaceuticals 2011-2016 74
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Dicerna Pharmaceuticals 2011-2016 74
Table Mirna Therapeutics Company Profile 75
Figure Research Information of Mirna Therapeutics 76
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Mirna Therapeutics 2011-2016 76
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Mirna Therapeutics 2011-2016 77
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Mirna Therapeutics 2011-2016 77
Table Quark Pharmaceuticals Company Profile 78
Figure RNAi for Therapeutic Research Information of Quark Pharmaceuticals 79
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Quark Pharmaceuticals 2011-2016 79
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Quark Pharmaceuticals 2011-2016 80
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Quark Pharmaceuticals 2011-2016 81
Table RXi Pharmaceuticals Company Profile 81
Figure Research Information of RXi Pharmaceuticals 82
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of RXi Pharmaceuticals 2011-2016 83
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of RXi Pharmaceuticals 2011-2016 83
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of RXi Pharmaceuticals 2011-2016 84
Table Silence Therapeutics Company Profile 84
Figure RNAi for Therapeutic Research Information of Silence Therapeutics 85
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Silence Therapeutics 2011-2016 86
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Silence Therapeutics 2011-2016 86
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Silence Therapeutics 2011-2016 87
Table Benitec Biopharma Company Profile 87
Figure RNAi for Therapeutic Research Information of Benitec Biopharma 88
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Benitec Biopharma 2011-2016 88
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Benitec Biopharma 2011-2016 89
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Benitec Biopharma 2011-2016 90
Table miRagen Therapeutics Company Profile 90
Figure RNAi for Therapeutic Research Information of miRagen Therapeutics 91
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of miRagen Therapeutics 2011-2016 92
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of miRagen Therapeutics 2011-2016 92
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of miRagen Therapeutics 2011-2016 93
Table Sylentis Company Profile 93
Figure RNAi for Therapeutic Research Information of Sylentis 94
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Sylentis 2011-2016 95
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Sylentis 2011-2016 95
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Sylentis 2011-2016 96
Table Gradalis Company Profile 96
Figure RNAi for Therapeutic Research Information of Gradalis 97
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Gradalis 2011-2016 97
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Gradalis 2011-2016 98
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Gradalis 2011-2016 98
Table Sirnaomics Company Profile 99
Figure RNAi for Therapeutic Research Information of Sirnaomics 100
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Sirnaomics 2011-2016 100
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Sirnaomics 2011-2016 101
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Sirnaomics 2011-2016 101
Table Silenseed Company Profile 102
Figure RNAi for Therapeutic Research Information of Silenseed 103
Table RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and R&D Share of Silenseed 2011-2016 103
Figure RNAi for Therapeutic Expenses (K USD), R&D Expenses (K USD) and Growth Rate of Silenseed 2011-2016 104
Figure RNAi for Therapeutic Expenses (K USD) and Global Market Share of Silenseed 2011-2016 104
Table 2011-2016E Global RNAi for Therapeutic Expenses (K USD) by Countries 105
Figure 2011 Global RNAi for Therapeutic Expenses Market Share 105
Figure 2012 Global RNAi for Therapeutic Expenses Market Share 106
Figure 2013 Global RNAi for Therapeutic Expenses Market Share 106
Figure 2014 Global RNAi for Therapeutic Expenses Market Share 107
Figure 2015 Global RNAi for Therapeutic Expenses Market Share 107
Figure Manufacturing Process Analysis of RNAi for Therapeutic 108
Table Key Manufacturer’s Collaborations of RNAi for Therapeutic 108
Table New Project SWOT Analysis of RNAi for Therapeutic 112

Request a Sample Copy

  • * :
  • * :
  • * :
  • * :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top